Feedback
Settings

Settings

Goto Application

1. WO2022003583 - AMINOPYRIMIDINYL DERIVATIVES

Submit observation
PermaLink
Publication Number WO/2022/003583
Publication Date 06.01.2022
International Application No. PCT/IB2021/055851
International Filing Date 30.06.2021
IPC
C07D 487/08 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
487Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/-C07D477/183
02in which the condensed system contains two hetero rings
08Bridged systems
A61P 35/00 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
A61P 37/00 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
37Drugs for immunological or allergic disorders
A61K 31/4995 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
4995Pyrazines or piperazines forming part of bridged ring systems
Applicants
  • PFIZER INC. [US]/[US]
Inventors
  • GERSTENBERGER, Brian Stephen
  • JIAO, Wenhua
  • LALL, Manjinder Singh
  • LIRA, Ricardo
  • SCHNUTE, Mark Edward
Agents
  • ZIELINSKI, Bryan C.
Priority Data
63/047,60602.07.2020US
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) AMINOPYRIMIDINYL DERIVATIVES
(FR) DÉRIVÉS D'AMINOPYRIMIDINYLE
front page image
Abstract
(EN) A compound of formula I: or a pharmaceutically acceptable salt thereof, wherein R1 and R2 are each independently hydrogen or hydroxy; wherein R1 and R2 are not both hydroxy. Also provided are methods of treatment as Janus Kinase inhibitors and pharmaceutical compositions containing the compounds of the invention and combinations thereof with other therapeutic agents.
(FR) L'Invention concerne un composé de formule I : ou un sel pharmaceutiquement acceptable de celui-ci, dans laquelle R1 et R2 représentent chacun indépendamment de l'hydrogène ou de l'hydroxy; dans laquelle R1 et R2 ne sont pas tous les deux de l'hydroxy. L'invention concerne également des procédés de traitement en tant qu'inhibiteurs de Janus Kinase et des compositions pharmaceutiques contenant les composés de l'invention et des combinaisons de ceux-ci avec d'autres agents thérapeutiques.
Latest bibliographic data on file with the International Bureau
# -